SHP2

Latest Updates of Viva's Portfolio Companies

Retrieved on: 
Monday, December 4, 2023

TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--On Nov. 29th, Phenomic AI ("Phenomic"), invested and incubated by Viva BioInnovator (VBI), announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers. The partners will leverage Phenomic's expertise in target identification and stromal biology based on its scTx® single-cell transcriptomics platform which will greatly enhance Boehringer's efforts to develop first-in-class medicines to transform the lives of people with cancer by delivering meaningful advances with the ultimate goal to cure a range of cancers. Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones. Phenomic is also eligible to receive more than USD $500 million in licensing fees as well as clinical, regulatory and commercial milestones in addition to royalties on future product sales.

Key Points: 
  • HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development.
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva's portfolio companies have new updates.
  • Phenomic will receive upfront and near-term payments of approximately $9 million including research funding and collaboration milestones.

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023

REDWOOD CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.

Key Points: 
  • Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.
  • CCR8 is a chemokine receptor predominantly expressed by tumor infiltrating Tregs that suppress the body’s natural anti-cancer immune response.
  • Targeting CCR8 is a promising potential therapeutic strategy designed to deplete Tregs, reshape the tumor microenvironment and enhance anti-tumor immune response.
  • Data presented compare mechanistic data for LOQTORZI™ to commercially available anti-PD-1 monoclonal antibodies and demonstrate higher expression of key immune system biomarkers with LOQTORZI™.

Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO

Retrieved on: 
Sunday, October 22, 2023

The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.

Key Points: 
  • The results of this clinical trial validated the safety and efficacy of the combination therapy of glecirasib and JAB-3312, which laid a foundation for a further registrational clinical trial.
  • Jacobio presented results of a Phase I/IIa study of glecirasib in combination with JAB-3312.
  • The ORR was 86.7% (13/15) in the dose group[1] of 800 mg glecirasib in combination with 2 mg JAB-3312.
  • "The data provides the basis for the registrational clinical study of glecirasib in combination with SHP2 inhibitor.

Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023

REDWOOD CITY, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 14, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced a presentation of toripalimab data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023 at the Hynes Convention Center in Boston.
  • PD-L1, a protein found on the surface of some cancer cells, suppresses T cell activation and inhibits the ability of the body’s immune system to kill cancer cells.
  • Toripalimab is an anti-PD-1 monoclonal antibody that binds with high affinity to a unique site on PD-1, thereby blocking the interaction of PD-1 and PD-L1.
  • “PD-1 inhibition has been a significant advancement in cancer treatment across tumor types but better treatments are needed to increase response rates and drive improved outcomes for patients.

InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib

Retrieved on: 
Thursday, September 14, 2023

Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations and other uncommon EGFR mutations.

Key Points: 
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations and other uncommon EGFR mutations.
  • ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
  • Dr. Jasmine Cui, Co-Founder, Chairwoman and CEO of InnoCare, said: “SHP2 inhibitor is an ideal partner for combination with multiple targeted and immune-oncology therapies in the field of solid tumor.
  • We will work with ArriVent to accelerate clinical development of the combination of ICP-189 and furmonertinib, so that this innovative therapy can benefit patients with advanced NSCLC earlier."

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, August 10, 2023

 SAN DIEGO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended June 30, 2023, and provided business updates.

Key Points: 
  • Strengthened Business Leadership: In May 2023, Erasca promoted David Chacko, M.D., previously Erasca’s chief financial officer, to the dual position of chief financial officer and chief business officer, and Nik Chetwyn, Ph.D., previously Erasca’s senior vice president of operations, to chief operating officer.
  • Erasca expects its current cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2025.
  • Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the quarter ended June 30, 2023, compared to $27.5 million for the quarter ended June 30, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $9.8 million for the quarter ended June 30, 2023, compared to $8.4 million for the quarter ended June 30, 2022.

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

Retrieved on: 
Tuesday, August 8, 2023

REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2023, and provided an update on corporate progress.

Key Points: 
  • Webcast today at 4:30 p.m. Eastern Time
    REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2023, and provided an update on corporate progress.
  • “With growing confidence in our pioneering RAS-focused drug candidate pipeline, we believe Revolution Medicines is poised for a transformative second half of the year.
  • Additional details can be found in the announcement press release as well as in Revolution Medicines’ and EQRx’s SEC filings.
  • Revolution Medicines will host a webcast this afternoon, August 8, 2023, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

Retrieved on: 
Thursday, August 3, 2023

SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/MAPK pathway to regulate cellular proliferation and survival.

Key Points: 
  • SHP2 is a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signaling with the downstream RAS/MAPK pathway to regulate cellular proliferation and survival.
  • EGFR mutations occur in approximately 40-50% of NSCLC cases in Asia, more than twice the rate observed in the United States.
  • "BBP-398 is a potential best-in-class SHP2 inhibitor that was designed to maximize combination potential,” said Yizhe Wang, Ph.D., Chief Executive Officer of LianBio.
  • In July 2023, LianBio announced a clinical supply agreement with AstraZeneca in China to procure osimertinib for this trial.

Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference

Retrieved on: 
Friday, July 21, 2023

The presentation details are as follows:

Key Points: 
  • The presentation details are as follows:
    "We are extremely excited to have the opportunity for an oral presentation at 2023 ESMO Congress, and we hope our data will shed light on clinical development of SHP2 inhibitors in solid tumors.
  • Jacobio previously presented preclinical results of the above combination at the 2022 ESMO Asia Congress, demonstrating the combination of JAB-21822 and JAB-3122 synergistically inhibited tumor growth in multiple KRAS G12C inhibitor-resistant models.
  • This suggests that the combination of JAB-21822 and JAB-3312 may overcome resistance to KRAS G12C inhibitor in cancer patients.
  • ESMO Congress 2023 will be held in Madrid, Spain, from October 20 to October 24.

InnoCare and ArriVent Announce Clinical Development Collaboration

Retrieved on: 
Friday, July 14, 2023

Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations.

Key Points: 
  • Furmonertinib is being advanced by ArriVent in global studies in patients with advanced or metastatic NSCLC with EGFR or HER2 mutations, including exon 20 insertion mutations.
  • Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said: “NSCLC is the major subtype of lung cancer with huge unmet medical needs.
  • We are glad to work with ArriVent to push forward the combination study and expect this innovative therapy to benefit global patients early.”
    “We are excited to announce this clinical development collaboration with InnoCare,” said Bing Yao, Ph.D., Chairman, Co-founder and Chief Executive Officer of ArriVent.
  • “Combining furmonertinib with ICP-189 represents the growing opportunity for our furmonertinib clinical development program, in addition to ongoing studies in the monotherapy setting.